Sanofi GMP Problems Require Top-level Sit-down With FDA, But Product Impact Limited So Far

Agency’s warning letter also includes an uncommon request for a “global assessment” of operations. FDA says sterility of TheraCys lots manufactured since 2000 cannot be assured; company has halted manufacture of the bladder cancer drug and set limits on orders of its Pentacel vaccine.

FDA has requested a meeting with Sanofi’s senior management to discuss a host of manufacturing problems – from inadequate sterility testing to the nesting of birds in air units – at two of the company’s facilities.

The call for a meeting with the company is uncommon and indicates the seriousness of the violations. Among current good...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

New Advisory Group To Shape UK’s Simplified Informed Consent Process

 

Although the UK Health Research Authority’s initial proposal for simplified informed consent was rejected by stakeholders, it has yielded valuable insights into reducing trial burden and widening access

Ultragenyx Says CRL Discussions ‘Productive’ Despite US FDA Leadership Upheaval

 

Ultragenyx said talks with the FDA about a path forward after receiving a CRL for UX111 have been productive despite the recent upheaval at the agency.

Prasad 2.0 Brings New Instability Concerns, Questions About Changed Regulatory Philosophy

 

Many agency stakeholders believe Vinay Prasad may be forced to change his regulatory approach at least somewhat after receiving a second chance to lead the US FDA's biologics center.